Preliminary results of absorbable magnesium stent for treating eustachian tube dysfunction in a porcine model

PLoS One. 2023 Apr 25;18(4):e0284584. doi: 10.1371/journal.pone.0284584. eCollection 2023.

Abstract

Absorbable magnesium (Mg) stents have an attractive biocompatibility and rapid degradation rate, but their degradable behavior and efficacy in the Eustachian tube (ET) have not yet been investigated. In this study, the degradable behavior of the Mg stent in artificial nasal mucus was evaluated. The Mg stents in the porcine ET model were also investigated to evaluate their safety and efficacy. Four Mg stents were placed into the four ETs of two pigs. The mass loss rate of the Mg stents gradually decreased over time. The decrease rates were 30.96% at one week, 49.00% at two weeks, and 71.80% at four weeks. On the basis of histological findings, the thickness of submucosal tissue hyperplasia and the degree of inflammatory cell infiltration significantly decreased at four weeks compared with two weeks. Biodegradation of the Mg stent occurred before tissue proliferative reactions, and the ET patency was successfully maintained without stent-induced tissue hyperplasia at four weeks. The Mg stent that biodegrades rapidly seems to be effective and safe in porcine ET. Further investigation is required to verify the optimal stent shape and indwell period in the ET.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Absorbable Implants
  • Animals
  • Eustachian Tube* / surgery
  • Hyperplasia
  • Magnesium*
  • Stents
  • Swine

Substances

  • Magnesium

Grants and funding

This study was supported by a National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT; Ministry of Science, ICT; no. 2020R1F1A1049412). This research was supported by the Nano Material Technology Development Program through the National Research Foundation of Korea(NRF), funded by the Ministry of Science and ICT (No. 2022M3H4A1A04085300). This study was supported by a grant (2023IE0005) from the Asan Institute for Life Sciences, Asan Medical Center, Seoul, Korea.